Patient-Friendly Explanation

Immune cells contain a protein complex called the NLRP3 inflammasome. In obesity it is switched on far too often and releases powerful inflammatory signals. That constant low-level inflammation helps explain insulin resistance, fatty liver and blood vessel damage.

Clinical Definition

The NLRP3 inflammasome is a cytosolic multiprotein sensor that assembles in response to danger signals such as extracellular ATP, cholesterol crystals, ceramides and mitochondrial reactive oxygen species. Assembly activates caspase-1, which cleaves pro-interleukin-1 beta and pro-interleukin-18 into their active forms. Adipose tissue macrophages and hepatocytes in obesity show increased NLRP3 activation, and the resulting interleukin-1 beta impairs insulin signalling in adipose tissue, liver and skeletal muscle while contributing to beta-cell dysfunction.

Why It Matters

This pathway is why anti-inflammatory strategies, including colchicine as an NLRP3 inhibitor, are being studied in cardiometabolic disease. NuLifeCare Singapore treats inflammation-driven metabolic risk as part of its structured weight management programme.